Could Save Thousands of Lives a Day
This Little Pill
Phase II Clinical Trial Approaching Conclusion
™
Nocturol
Patents also granted in 6 other countries.
Worldwide protection underway.
U.S. patents
9
Finally there's a solution
Nocturia
Focused on improving the lives of hundreds of millions of people.
The focus of Wellesley Pharmaceuticals is to help people sleep better with fewer or no interruptions due to the urge to urinate periodically throughout the night.
We are currently in development of Nocturol™ (also known as Paxerol®), a treatment for nocturia in order to reduce these bathroom visits and enable a more peaceful and healthy sleep.
Sleep Undisturbed
Nocturol inhibits the overproduction of prostaglandins with a low dose combination of acetaminophen and ibuprofen in an extended release formulation. For those who suffer from frequent nightly bathroom trips, Nocturol is designed to provide 8 hours of protection with one nightly tablet.
A Breakthrough Leading to Big Impact
The Phase 2 double-blinded clinical trial of Nocturol conducted in New York City and Long Island, NY was recently concluded with record setting results and no side effects reported.
Has Identified The Key
Our science has unlocked the key to inhibiting prostaglandins through a synergistic combination of acetaminophen and NSAIDs. Ibuprofen inhibits production at the COX site and acetaminophen inhibits production at the POX site, both within the COX1/2 enzymes.
Questions about Wellesley Pharmaceuticals or Nocturol?
